New publication emphasizes need to determine timing of anticoagulants for some stroke patients

AUSTIN – November 14, 2018 – A new review of optimal timing for anticoagulation in acute stroke patients emphasizes the importance of our consortium’s START trial. Dr. Steven Warach, LSS Executive Director, and colleagues looked at evidence on the best time to initiate blood thinners after ischemic stroke in patients with atrial fibrillation. Their review is published in The Lancet. 

START is the first study of its kind in the United States to randomize when these patients should begin their treatment and compare the different groups’ rates of having recurrent strokes or bleeding events 30 days out from their stroke.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *